Breast Cancer Research and Treatment

, Volume 121, Issue 2, pp 373–378

ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer

  • Christoph Hirche
  • Dawid Murawa
  • Zarah Mohr
  • Soeren Kneif
  • Michael Hünerbein
Clinical trial

Abstract

Background: Sentinel lymph node (SLN) biopsy is a selective approach to axillary staging of breast cancer with reduced morbidity. Current detection methods including radioisotope and blue dye show good results but some drawbacks are remaining. Indocyanine green (ICG) fluorescence detection was evaluated as a new method for SLN biopsy in breast cancer allowing both transcutaneous visualization of lymphatic vessels and intraoperative identification of SLN. Methods: Forty-three women with clinically node negative breast cancer received subareolar injection of ICG for fluorescence detection of SLN. All patients underwent either planned axillary lymph node dissection (ALND) with SLN biopsy or selective SLN biopsy to determine need for ALND. Clinical feasibility, detection rate, sensitivity, and axillary recurrence after isolated SLN biopsy were analyzed. Results: Overall ICG fluorescence imaging identified 2.0 SLN in average in 42 of 43 patients (detection rate: 97.7%). Metastatic involvement of the SLN was found in 17 of 18 nodal positive patients by conventional histopathology (sensitivity: 94.4%). Immunohistochemistry revealed isolated tumor cells in five further cases. There was only one false-negative case in 43 patients (5.6%). In 17 of 23 overall nodal positive patients, the SLN was the only positive lymph node. After a median follow-up of 4.7 years none of the patients presented with axillary recurrence. Conclusion: ICG fluorescence imaging is a new method for SLN biopsy in breast cancer with acceptable sensitivity and specificity comparable to conventional methods. One advantage of this technique is that it allows transcutaneous visualization of lymphatic vessels and intraoperative lymph node detection without radioisotope.

Keywords

Sentinel lymph node biopsy Breast cancer Indocyanine green (ICG) Fluorescence imaging Surgery 

Abbreviations

ALND

Axillary lymph node dissection

ICG

Indocyanine green

SLN

Sentinel lymph node

References

  1. 1.
    Bonnema J, van de Velde CJ (2002) Sentinel lymph node biopsy in breast cancer. Ann Oncol 13:1531–1537CrossRefPubMedGoogle Scholar
  2. 2.
    Zavagno G, De Salvo GL, Scalco G et al (2008) A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 247:207–213CrossRefPubMedGoogle Scholar
  3. 3.
    Cox CE, Pendas S, Cox JM et al (1998) Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 227:645–651CrossRefPubMedGoogle Scholar
  4. 4.
    Langer I, Guller U, Hsu-Schmitz SF et al (2009) Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. Eur J Surg Oncol 35(8):805–813PubMedGoogle Scholar
  5. 5.
    Giuliano AE, Jones RC, Brennan M, Statman R (1997) Sentinel lymphadenectomy in breast cancer. J Clin Oncol 15:2345–2350PubMedGoogle Scholar
  6. 6.
    Liberman L (2000) Pathologic analysis of sentinel lymph nodes in breast carcinoma. Cancer 88:971–977CrossRefPubMedGoogle Scholar
  7. 7.
    Maaskant AJ, van de Poll-Franse LV, Voogd AC et al (2009) Stage migration due to introduction of the sentinel node procedure: a population-based study. Breast Cancer Res Treat 113:173–179CrossRefPubMedGoogle Scholar
  8. 8.
    Fleissig A, Fallowfield LJ, Langridge CI et al (2006) Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 95:279–293CrossRefPubMedGoogle Scholar
  9. 9.
    Sardi A, Spiegler E, Colandrea J et al (2002) The benefit of using two techniques for sentinel lymph node mapping in breast cancer. Am Surg 68:24–28PubMedGoogle Scholar
  10. 10.
    Upponi SS, McIntosh SA, Wishart GC et al (2002) Sentinel lymph node biopsy in breast cancer—is lymphoscintigraphy really necessary? Eur J Surg Oncol 28:479–480PubMedGoogle Scholar
  11. 11.
    Dauphine CE, Khalkhali I, Vargas MP et al (2006) Intraoperative injection of technetium-99 m sulfur colloid is effective in the detection of sentinel lymph nodes in breast cancer. Am J Surg 192:423–426CrossRefPubMedGoogle Scholar
  12. 12.
    Stratmann SL, McCarty TM, Kuhn JA (1999) Radiation safety with breast sentinel node biopsy. Am J Surg 178:454–457CrossRefPubMedGoogle Scholar
  13. 13.
    Rutgers EJ (2005) Guidelines to assure quality in breast cancer surgery. Eur J Surg Oncol 31:568–576CrossRefPubMedGoogle Scholar
  14. 14.
    Aydogan F, Celik V, Uras C et al (2008) A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg 195:277–278CrossRefPubMedGoogle Scholar
  15. 15.
    Raut CP, Hunt KK, Akins JS et al (2005) Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer 104:692–699CrossRefPubMedGoogle Scholar
  16. 16.
    Wilke LG, McCall LM, Posther KE et al (2006) Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 13:491–500CrossRefPubMedGoogle Scholar
  17. 17.
    Cox CE, Bass SS, Reintgen DS (1999) Techniques for lymphatic mapping in breast carcinoma. Surg Oncol Clin North Am 8:447–468Google Scholar
  18. 18.
    Sandrucci S, Casalegno PS, Percivale P et al (1999) Sentinel lymph node mapping and biopsy for breast cancer: a review of the literature relative to 4791 procedures. Tumori 85:425–434PubMedGoogle Scholar
  19. 19.
    Ogasawara Y, Ikeda H, Takahashi M et al (2008) Evaluation of breast lymphatic pathways with indocyanine green fluorescence imaging in patients with breast cancer. World J Surg 32(9):1924–1929CrossRefPubMedGoogle Scholar
  20. 20.
    Kitai T, Inomoto T, Miwa M, Shikayama T (2005) Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer 12:211–215CrossRefPubMedGoogle Scholar
  21. 21.
    Meyer JS (1998) Sentinel lymph node biopsy: strategies for pathologic examination of the specimen. J Surg Oncol 69:212–218CrossRefPubMedGoogle Scholar
  22. 22.
    Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187CrossRefPubMedGoogle Scholar
  23. 23.
    Layeequr RR, Siegel E, Boneti C et al (2009) Stage migration with sentinel node biopsy in breast cancer. Am J Surg 197:491–496CrossRefGoogle Scholar
  24. 24.
    McIntosh SA, Ravichandran D, Balan KK (2001) Sentinel lymph node biopsy in impalpable breast cancer. Breast 10:82–83CrossRefPubMedGoogle Scholar
  25. 25.
    Woznick A, Franco M, Bendick P, Benitez PR (2006) Sentinel lymph node dissection for breast cancer: how many nodes are enough and which technique is optimal? Am J Surg 191:330–333CrossRefPubMedGoogle Scholar
  26. 26.
    Tagaya N, Yamazaki R, Nakagawa A et al (2008) Intraoperative identification of sentinel lymph nodes by near-infrared fluorescence imaging in patients with breast cancer. Am J Surg 195:850–853CrossRefPubMedGoogle Scholar
  27. 27.
    Murawa D, Hirche C, Dresel S, Hunerbein M (2009) Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence. Br J Surg 96:1289–1294CrossRefPubMedGoogle Scholar
  28. 28.
    Tafra L, Lannin DR, Swanson MS et al (2001) Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 233:51–59CrossRefPubMedGoogle Scholar
  29. 29.
    Motomura K, Inaji H, Komoike Y et al (1999) Sentinel node biopsy guided by indocyanine green dye in breast cancer patients. Jpn J Clin Oncol 29:604–607CrossRefPubMedGoogle Scholar
  30. 30.
    Hama Y, Koyama Y, Urano Y et al (2007) Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity. Breast Cancer Res Treat 103:23–28CrossRefPubMedGoogle Scholar
  31. 31.
    Cserni G, Bianchi S, Vezzosi V (2008) Variations in sentinel node isolated tumour cells/micrometastasis and non-sentinel node involvement rates according to different interpretations of the TNM definitions. Eur J Cancer 44:2185–2191CrossRefPubMedGoogle Scholar
  32. 32.
    Stitzenberg KB, Calvo BF, Iacocca MV et al (2002) Cytokeratin immunohistochemical validation of the sentinel node hypothesis in patients with breast cancer. Am J Clin Pathol 117:729–737PubMedGoogle Scholar
  33. 33.
    Patani N, Mokbel K (2009) The clinical significance of sentinel lymph node micrometastasis in breast cancer. Breast Cancer Res Treat 114:393–402CrossRefPubMedGoogle Scholar
  34. 34.
    Langer I, Guller U, Berclaz G et al (2009) Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study. Breast Cancer Res Treat 113:129–136CrossRefPubMedGoogle Scholar
  35. 35.
    Chung MA, Steinhoff MM, Cady B (2002) Clinical axillary recurrence in breast cancer patients after a negative sentinel node biopsy. Am J Surg 184:310–314CrossRefPubMedGoogle Scholar
  36. 36.
    Bergkvist L, de Boniface J, Jonsson PE et al (2008) Axillary recurrence rate after negative sentinel node biopsy in breast cancer: three-year follow-up of the Swedish Multicenter Cohort Study. Ann Surg 247:150–156CrossRefPubMedGoogle Scholar
  37. 37.
    Langer I, Marti WR, Guller U et al (2005) Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 241:152–158PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Christoph Hirche
    • 1
  • Dawid Murawa
    • 1
  • Zarah Mohr
    • 1
  • Soeren Kneif
    • 1
  • Michael Hünerbein
    • 1
  1. 1.Department of General Surgery and Surgical OncologyRobert-Rössle-Klinik, Helios Hospital Berlin-Buch, CCBBerlinGermany

Personalised recommendations